Lupeol-Rich Extract Stimulates HSP47 for Connective Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for connective tissue degeneration, such as in the skin, joints, and gingival connective tissues, are inadequate in stimulating collagen synthesis and preventing degeneration caused by internal or external shocks, leading to structural anomalies and impaired mechanical support.
Innovation Solution
A lupeol-rich extract with a content of greater than 30% by weight is used to stimulate the synthesis of heat shock proteins, particularly HSP47, promoting collagen production and fibroblast/chondrocyte activity, thereby addressing collagen production anomalies and preventing tissue degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for connective tissue degeneration, then existing therapeutic approaches are maintained, but collagen synthesis stimulation is inadequate and tissue degeneration continues
Solution Approach 1:
The patent applies parameter changes by introducing a lupeol-rich extract (with lupeol content >30% by weight) that specifically stimulates heat shock protein synthesis. This changes the biochemical parameters of tissue repair, shifting from conventional treatments to a mechanism-driven approach that upregulates HSP47 and enhances collagen production, thereby resolving the contradiction between treatment reliability and collagen synthesis productivity
Solution Approach 2:
The patent uses heat shock proteins, particularly HSP47, as intermediary molecules that mediate between the lupeol-rich extract and collagen synthesis. HSP47 acts as a chaperone protein that facilitates proper collagen folding and assembly, serving as a molecular intermediary that amplifies the effect of lupeol on collagen production, thus improving both treatment effectiveness and collagen synthesis rate
2Object-affected harmful factors
If connective tissues are exposed to physical constraints, UV radiation, or other stressors, then structural anomalies occur and mechanical support is impaired, but no effective prevention is provided
Solution Approach 1:
The patent applies preliminary action by using the lupeol-rich extract to pre-stimulate heat shock protein synthesis before connective tissues are exposed to damaging stressors. This preemptive upregulation of HSP47 prepares the collagen network for potential damage, enhancing its resilience and preventing structural anomalies before they occur, thereby addressing both resistance to stressors and collagen network stability
Solution Approach 2:
The patent implements beforehand cushioning through the protective effect of heat shock proteins that are upregulated by lupeol treatment. These chaperone proteins cushion the collagen network against the harmful effects of UV radiation, physical constraints, and other stressors by preventing improper protein folding and aggregation, thus protecting collagen integrity before damage occurs
Data Source
AI summary
The present invention relates to the use of a lupeol-rich extract for the production of a cosmetic or pharmaceutical composition for treating and/or preventing a connective tissue degeneration. Said invention also relates to the use of a lupeol-rich extract for the production of a pharmaceutical composition for preventing and/or treating non-inflammatory articular pathologies, periodontal diseases and stretch marks. The invention also relates to the use of a lupeol-rich extract for the production of a cosmetic composition as a cicatrizing agent, a restructuring agent and an anti-sagging agent for skin and/or mucosae.